RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+7.28%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$622M
AUM Growth
+$622M
(-18%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-16.52%
Top 10 Holdings %
Top 10 Hldgs %
70.49%
Holding
49
New
24
Increased
5
Reduced
10
Closed
5
Top Buys
| 1 |
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
|
$64.2M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
$37.9M |
| 3 |
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
|
$22.1M |
| 4 |
TG Therapeutics
TGTX
|
$22M |
| 5 |
Larimar Therapeutics
LRMR
|
$14.4M |
Top Sells
| 1 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$158M |
| 2 |
Enanta Pharmaceuticals
ENTA
|
$51M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
$22M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
$21.1M |
| 5 |
Sangamo Therapeutics
SGMO
|
$16.9M |
Sector Composition
| 1 | Healthcare | 67.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DYAX
1
DELISTED
DYAX CORPORATION
DYAX
| $79M | 9.34% | 7,809,139 -2,173,439 | -22% | -$22M |
|
|
2
BioCryst Pharmaceuticals
BCRX
$1.74B
| $69.1M | 8.17% | 7,069,159 +3,870,630 | +121% | +$37.9M |
|
|
ACHN
3
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $66.9M | 7.9% | 6,700,000 -15,786,007 | -70% | -$158M |
|
|
AVNR
4
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
| $64.2M | 7.59% | +5,386,700 | New | +$64.2M |
|
|
VIRX
5
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $34.8M | 4.11% | 4,869,261 | – | – |
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $30.9M | 3.65% | 2,428,571 | – | – |
|
|
BLUE
7
DELISTED
bluebird bio
BLUE
| $26.2M | 3.09% | 728,812 +225,750 | +45% | +$8.1M |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $22.9M | 2.71% | 588,941 +61,000 | +12% | +$2.37M |
|
|
ZSPH
9
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $22.1M | 2.62% | +564,483 | New | +$22.1M |
|
|
10
TG Therapeutics
TGTX
$4.65B
| $22M | 2.6% | +2,065,571 | New | +$22M |
|
11
Novavax
NVAX
$1.21B
| $21.1M | 2.5% | 5,067,083 -1,594,648 | -24% | -$6.65M |
|
12
Dynavax Technologies
DVAX
$1.19B
| $17.4M | 2.06% | 12,179,002 -1,857,588 | -13% | -$2.66M |
|
|
ARAV
13
DELISTED
Aravive, Inc. Common Stock
ARAV
| $17.1M | 2.02% | 898,993 -304,009 | -25% | -$5.77M |
|
14
TherapeuticsMD
TXMD
$12.8M
| $16M | 1.89% | 3,454,332 -848,734 | -20% | -$3.94M |
|
|
15
Larimar Therapeutics
LRMR
$310M
| $14.4M | 1.7% | +732,960 | New | +$14.4M |
|
16
Akebia Therapeutics
AKBA
$833M
| $13.2M | 1.56% | 597,363 | – | – |
|
|
17
Sangamo Therapeutics
SGMO
$157M
| $13.2M | 1.56% | 1,220,209 -1,571,096 | -56% | -$16.9M |
|
18
Xencor
XNCR
$580M
| $11.6M | 1.37% | 1,248,923 +232,188 | +23% | +$2.16M |
|
|
19
Enanta Pharmaceuticals
ENTA
$180M
| $9.89M | 1.17% | 250,000 -1,289,586 | -84% | -$51M |
|
20
Tenax Therapeutics
TENX
$27.3M
| $9.18M | 1.09% | 2,336,375 +2,021,077 | +641% | +$7.94M |
|
21
SCYNEXIS
SCYX
$34.9M
| $6.21M | 0.73% | 840,000 | – | – |
|
|
FRTX
22
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $6.13M | 0.72% | +5,475,419 | New | +$6.13M |
|
|
CYTO
23
DELISTED
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)
CYTO
| $5.42M | 0.64% | +940,000 | New | +$5.42M |
|
|
TTOO
24
DELISTED
T2 Biosystems, Inc
TTOO
| $2.5M | 0.29% | +138,002 | New | +$2.5M |
|
|
WGBS
25
DELISTED
WaferGen Bio-systems, Inc.
WGBS
| $2.44M | 0.29% | +560,000 | New | +$2.44M |
|